Stocks Health care NUVB
NYSE · Health careNuvation Bio Inc. (NUVB)
Nuvation Bio Inc. brought in $201.7M of revenue over the twelve months to September 30, 2026, up 654.2% from a year earlier. It posted a net loss of $135.9M. In fiscal 2025 capital spending exceeded operating cash flow by $181.4M. At September 30, 2026 it held $153.8M in cash against $279.5M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 4, 2026.
Key facts about Nuvation Bio Inc.
- Net worth
- Nuvation Bio Inc. has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $228M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $62.9M (+699.0% year on year), with a net loss of $204.6M. Over the 12 months to September 30, 2026: revenue $201.7M, net loss $135.9M.
- Cash flow
- In fiscal 2025 operations used $173.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 4, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Nuvation Bio Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Nuvation Bio Inc. does
Nuvation Bio Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker NUVB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $62.9M | -$204.6M | -$0.60 | -$181.4M |
| 2024 | $7.9M | -$567.9M | -$2.11 | -$130.4M |
| 2023 | $0 | -$75.8M | -$0.35 | n/a |
| 2022 | n/a | -$104.2M | -$0.48 | n/a |
| 2021 | n/a | -$86.8M | -$0.44 | n/a |
| 2020 | n/a | -$41.7M | -$0.43 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where NUVB ranks in Health care
Latest SEC filings
What Nuvation Bio Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 4, 2026
- November 4, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 243% to $45M versus the same quarter last year; diluted EPS -$0.12 versus -$0.16.
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 556% to $31.7M versus the same quarter last year; diluted EPS -$0.18 versus -$0.17.
- July 6, 2026New debt 8-K
- June 30, 2026
- June 29, 2026Form 305B2 filing 305B2
- May 27, 2026
- May 4, 2026
- May 4, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 2,599% to $83.2M versus the same quarter last year; diluted EPS $0.01 versus -$0.16.
Insider trades
What the people running Nuvation Bio Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $709.2K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 19, 2026 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Exercised options | 100,000 | $187K |
| August 19, 2026 | Hattersley GaryCHIEF SCIENTIFIC OFFICER | Soldpre-planned (10b5-1) | 100,000 | $709.2K |
| July 15, 2026 | Sauvage PhilippeChief Financial Officer | Exercised options | 39,999 | $86.8K |
| July 15, 2026 | Sauvage PhilippeChief Financial Officer | Exercised options | 1 | $2 |
| June 23, 2026 | Wentworth KerryCHIEF REGULATORY OFFICER | Exercised options | 63,000 | $184.6K |
| June 23, 2026 | Wentworth KerryCHIEF REGULATORY OFFICER | Soldpre-planned (10b5-1) | 63,000 | $379.2K |
| June 23, 2026 | Markel StacyCHIEF PEOPLE OFFICER | Exercised options | 90,380 | $169K |
| June 23, 2026 | Markel StacyCHIEF PEOPLE OFFICER | Exercised options | 34,620 | $60.2K |
Who owns NUVB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| David Hung, M.D.13D, may seek influence | 27.7% | March 26, 2024 |
| Fmr LLC13G, passive with 1 related filers | 15% | May 12, 2025 |
| Xiangmin Cui13D, may seek influence with 5 related filers | 8% | September 10, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 244 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 52,230,295 | +240,702 |
| BlackRock, Inc. | 27,630,837 | +2,530,463 |
| Decheng Capital LLC | 25,954,439 | 0 |
| Vanguard Capital Management LLC | 11,919,514 | +293,316 |
| Omega Fund Management, LLC | 8,081,089 | 0 |
| Laurion Capital Management LP | 7,820,013 | -2,625 |
| State Street Corp | 7,370,794 | +585,867 |
| Geode Capital Management, LLC | 6,244,805 | +381,151 |
| American Century Companies Inc | 4,499,643 | +1,602,565 |
| Bank of America Corp | 3,529,748 | +309,922 |
| Tang Capital Management LLC | 3,299,557 | +150,000 |
| Redmile Group, LLC | 3,031,009 | -122,247 |
| Vanguard Portfolio Management LLC | 2,688,666 | +413,220 |
| Aqr Capital Management LLC | 2,356,429 | +360,671 |
| Northern Trust Corp | 2,321,873 | +318,765 |
| Algert Global LLC | 2,277,358 | +435,280 |
| Charles Schwab Investment Management Inc | 2,058,870 | +66,419 |
| Dimensional Fund Advisors LP | 2,047,876 | -4,815 |
| Armistice Capital, LLC | 2,000,000 | +264,000 |
| Citadel Advisors LLC | 1,988,330 | -77,081 |
Insiders
7 insiders reported holding 474,859 shares in total, about $2.1M at the last price.
| Holder | Shares |
|---|---|
| Mashal RobertDirector | 225,000225,000 held indirectly |
| Makunje MosesSEE REMARKS | 68,137 |
| Sauvage PhilippeChief Financial Officer | 54,131 |
| Wentworth KerryCHIEF REGULATORY OFFICER | 53,000 |
| Markel StacyCHIEF PEOPLE OFFICER | 32,591 |
| Hanley David C.CHIEF TECHNICAL OPERATIONS | 24,000 |
| Liu DongfangCHIEF MEDICAL OFFICER | 18,000 |
Questions about NUVB
What does Nuvation Bio Inc. do?
Nuvation Bio Inc. is a company in the Health care sector, listed on NYSE as NUVB. Its shares trade on NYSE under the ticker NUVB.
What is Nuvation Bio Inc.'s net worth?
Nuvation Bio Inc. has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $228M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Nuvation Bio Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $135.9M on revenue of $201.7M.
How much revenue does Nuvation Bio Inc. make?
Over the twelve months to September 30, 2026 Nuvation Bio Inc. reported revenue of $201.7M. That is 654.2% more than a year earlier.
When did Nuvation Bio Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 4, 2026. It covers the period to September 30, 2026.
When is Nuvation Bio Inc.'s next earnings report?
Nuvation Bio Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare NUVB with
Follow NUVB
Get an email when Nuvation Bio Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Nuvation Bio Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.